Working… Menu

Pasireotide LAR in Severe Polycystic Liver Disease (SOM230)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01670110
Recruitment Status : Completed
First Posted : August 21, 2012
Results First Posted : March 2, 2020
Last Update Posted : May 1, 2020
Information provided by (Responsible Party):
Marie Hogan, Mayo Clinic

Brief Summary:
The purpose of this study is to compare SOM230 treatment to placebo. The investigators will also assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life.

Condition or disease Intervention/treatment Phase
Somatostatin Analogs Polycystic Liver Disease Autosomal Dominant Polycystic Kidney Disease Autosomal Dominant Polycystic Liver Disease Drug: Pasireotide LAR Drug: Placebo Phase 2

Detailed Description:

Pasireotide (SOM230) is a novel multi-receptor-targeted analog that has high affinity for four of the five SST receptor subtypes (SSTr1, SSTr2, SSTr3 and SSTr5); it has a 40-fold higher affinity and 158-fold higher functional activity for the SST5 receptor than octreotide. Because of its broad receptor binding profile, pasireotide may be more potent in Polycystic Liver Disease (PLD) than octreotide. In this randomized double blind placebo controlled trial the investigators will compare SOM230 treatment to placebo for 12 months in patients with PLD. The primary endpoints will be assessed at 12 months and patients receiving placebo then crossed over to SOM230, permitting all participants to receive SOM230 for the subsequent two years. Magnetic resonance imaging (MRI) will be used to assess liver volume - the primary endpoint, which will be assessed at baseline, end of years 1 and 3. This study will assess the efficacy and safety of SOM230 in reducing total liver volume and improving quality of life over 12 months. (The investigators will not be assessing efficacy at 24 months.) The therapy way be effective in PLD but also may prove to be effective for many more patients with Polycystic Kidney Disease (PKD) which will be evaluated using eGFR and kidney volume using MRI.

The investigators plan to add other sub-sites in other locations.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease
Actual Study Start Date : August 2012
Actual Primary Completion Date : September 2018
Actual Study Completion Date : September 2018

Arm Intervention/treatment
Active Comparator: Pasireotide LAR (SOM230)
Active Pasireotide LAR
Drug: Pasireotide LAR
Injectible, 60mg per month

Placebo Comparator: placebo injection Drug: Placebo
To be injected once per month

Primary Outcome Measures :
  1. Change in Liver Volume [ Time Frame: baseline , 12 month ]
    Percent change was calculated for liver volumes using the equation=[(12 month value-baseline value)/baseline value]*100*12/12 month

  2. Change in Kidney Volume [ Time Frame: baseline to 12 months ]
    Percent change was calculated for kidney volumes using the equation=[(12 month value-baseline value)/baseline value]*100*12/12 month

Secondary Outcome Measures :
  1. Percentage Change in Estimated Glomerular Filtration Rate (eGFR) [ Time Frame: Baseline, 12 months ]
    eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. This value at baseline and 12 months was used to calculate the percentage change by [12 month value-baseline value)/baseline value]*100

  2. Percentage Change in Serum Creatinine [ Time Frame: Baseline, 12 months ]
    Serum creatinine level at baseline and 12 months was used to calculate the percentage change by [12 month value-baseline value)/baseline value]*100

  3. Percent Change in Blood Glucose [ Time Frame: Baseline, 12 months ]
    Blood glucose (mg/dLb) level at baseline and 12 months was used to calculate the percentage change by [12 month value-baseline value)/baseline value]*100

  4. Percentage Change in Hemoglobin A1C [ Time Frame: Baseline, 12 months ]
    Hemoglobin A1C level at baseline and 12 months was used to calculate the percentage change by [12 month value-baseline value)/baseline value]*100

  5. Percentage Change in Heart Rate [ Time Frame: Baseline, 12 months ]
    Heart rate, measured in beats per minute (BPM), at baseline and 12 months was used to calculate the percentage change by [12 month value-baseline value)/baseline value]*100

  6. Change in Quality of Life [ Time Frame: Baseline, 12 months ]
    Measured using the SF-36 health survey, which consist of eight subscales each scored on a range of 0 to 100 (0=worst imaginable, 100=best imaginable). Change calculated from baseline = 12 month value-baseline value

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female Age ≥ 18 years.
  • Diagnosis of PLD associated with ADPKD (meeting the Modified Ravine's criteria) or isolated ADPLD (defined by the criteria described by Reynolds et al)
  • Severe PLD defined as a liver volume >4000mL or symptomatic disease due to mass effects from hepatic cysts (must be able to undergo MRI or CT scan to determine this).
  • Not a candidate for or declining surgical intervention.
  • Capable of providing informed consent.
  • Life expectancy ≥ 12 weeks
  • Patients with a known history of impaired fasting blood glucose (glucose >100 and <126) may be included at the discretion of the PI. These patients should be monitored closely throughout the trial and antihyperglycemic treatment adjusted as necessary. Patients that are deemed non eligible due to elevated glucose can be re-screened after adequate medical treatment.
  • Adequate end organ function as defined by:
  • Adequate bone marrow function:

    • WBC ≥ 2.5 x 109/L
    • Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
    • Platelets ≥ 100 x 109/L
    • Hb ≥ 9 g/dL
  • No evidence of significant liver disease:

    • Serum bilirubin ≤1.5 x ULN
    • INR < 1.3
    • ALT and AST ≤ 2 x ULN
  • Estimated glomerular filtration rate (eGFR) >30 ml/min/m2
  • Serum amylase and lipase ≤ 1.5 x ULN
  • Alkaline phosphatase ≤ 2.5 x ULN
  • Written informed consent obtained prior to any screening procedures
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures

Exclusion Criteria:

  • Patients will be considered ineligible for this study if they meet any of the following criteria:
  • Patients with a known hypersensitivity to SST analogs or any component of the pasireotide LAR or SQ formulations.
  • Patients with known malabsorption syndrome, short bowel or chologenic diarrhea not controlled by specific therapeutic means.
  • Patients with abnormal coagulation (PT or a PTT elevated by 30% above normal limits).
  • Patients on continuous anticoagulation therapy. Patients who were on anticoagulant therapy must complete a washout period of at least 10 days and have confirmed normal coagulation parameters before study inclusion.
  • Patients with symptomatic cholelithiasis.
  • Patients who are not biochemically euthyroid.
  • Patients with known history of hypothyroidism are eligible if they are on adequate and stable re-placement thyroid hormone therapy for at least 3 months.
  • Serum magnesium ≥ ULN
  • QT-related exclusion criteria:
  • QTcF at screening > 470 msec
  • Patients with a history of syncope or family history of idiopathic sudden death
  • Patients who have sustained or clinically significant cardiac arrhythmias
  • Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade AV block
  • Patients with concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure
  • Family history of long QT syndrome
  • Concomitant medications known to prolong the QT interval.
  • Potassium < or = to 3.5
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
  • Patients who have Uncontrolled diabetes as defined by HbA1c>8%* despite adequate therapy
  • Patients with the presence of active or suspected acute or chronic uncontrolled infection or with a history of immunodeficiency, including a positive HIV test result (ELISA and Western blot). An HIV test will not be required; however, previous medical history will be reviewed.
  • Non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with this study treatment.
  • Liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis or chronic persistent hepatitis.
  • Baseline ALT or AST >3x ULN
  • Patients with life-threatening autoimmune and ischemic disorders.
  • Uncontrolled hypertension
  • Patients who have a history of a primary malignancy, with the exception of locally excised non-melanoma skin cancer and carcinoma in situ of uterine cervix. (Patients who have had no evidence of disease from primary cancer for 3 or more years are allowed to participate in the study.)
  • History of pancreatitis
  • Patients with a known history of hepatitis B or C
  • Presence of Hepatitis B surface antigen (HbsAg)
  • Presence of Hepatitis C antibody (anti-HCV)
  • Patients with a history of, or current, alcohol misuse/abuse within the past 12 months
  • Known gallbladder or bile duct disease, acute or chronic pancreatitis
  • Patients who have any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the Investigator or the Sponsor's Medical Monitor
  • Use of an investigational drug within 1 month prior to dosing
  • Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01670110

Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Marie C Hogan, MD PhD Mayo Clinic
  Study Documents (Full-Text)

Documents provided by Marie Hogan, Mayo Clinic:
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Marie Hogan, Assistant Professor of Medicine, Mayo Clinic Identifier: NCT01670110    
Other Study ID Numbers: 11-007405
First Posted: August 21, 2012    Key Record Dates
Results First Posted: March 2, 2020
Last Update Posted: May 1, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Marie Hogan, Mayo Clinic:
Polycystic Liver Disease
Autosomal dominant polycystic kidney disease
Autosomal dominant polycystic liver disease
Somatostatin analogs
Pasireotide LAR
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Kidney Diseases
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant
Urologic Diseases
Digestive System Diseases
Joint Diseases
Musculoskeletal Diseases
Muscular Diseases
Musculoskeletal Abnormalities
Congenital Abnormalities
Kidney Diseases, Cystic
Abnormalities, Multiple
Genetic Diseases, Inborn
Pathological Conditions, Anatomical
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs